The major areas of research interest is to build a comprehensive program of research on the serology of HPV natural infection and HPV vaccination. These studies utilize the biobank of specimens from the various studies on HPV in DCEG such as the Costa Rica HPV16/18 Vaccine trial. We will examine the immunological determinants of protection recently reported for the HPV-16/18 vaccine against infection with other, phylogenetically related HPV types. Since protection against heterologous HPV types is partial, vaccine failures for these HPV types are expected in the early years following vaccination. We will also perform a nested case-control study within CVT that will evaluate key immunological markers among vaccinated women who develop infections with the types for which partial protection has been observed (failures), and will compare them to those observed among a group of controls who did not develop these infections after vaccination (successes). This effort is expected to be a multiyear project that will require initial validation and evaluation of novel immunological markers that can subsequently be applied in the nested case-control study.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Division of Cancer Epidemiology and Genetics
Zip Code
Castellsagué, Xavier; Naud, Paulo; Chow, Song-Nan et al. (2014) Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis 210:517-34
Safaeian, Mahboobeh; Johnson, Lisa G; Yu, Kai et al. (2014) Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma. Front Oncol 4:119
LaMontagne, D Scott; Mugisha, Emmanuel; Pan, Yuanji et al. (2014) Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine 32:6303-11
Robbins, Hilary A; Li, Yan; Porras, Carolina et al. (2014) Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis 14:120
Safaeian, Mahboobeh; Rodriguez, Ana Cecilia (2014) Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol 180:1076-81
Safaeian, Mahboobeh; Rajaraman, Preetha; Hartge, Patricia et al. (2013) Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk. Cancer Causes Control 24:1885-91
Lin, Shih-Wen; Ghosh, Arpita; Porras, Carolina et al. (2013) HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One 8:e53067
Safaeian, Mahboobeh; Sherman, Mark E (2013) From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination. J Natl Cancer Inst 105:1524-6
Safaeian, Mahboobeh; Ghosh, Arpita; Porras, Carolina et al. (2012) Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 21:1547-54
Coseo, Sarah E; Porras, Carolina; Dodd, Lori E et al. (2011) Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sex Transm Dis 38:976-82

Showing the most recent 10 out of 15 publications